Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings.

ABSTRACT:

Background

Fruquintinib, a standard third-line treatment option for metastatic colorectal cancer (mCRC), has been shown to significantly prolong both overall survival (OS) and progression-free survival (PFS) in patients. However, we have observed that the standard dosing of fruquintinib is frequently associated with a higher incidence of adverse effects within the Chinese population, leading some patients-particularly elderly individuals-to be unable to tolerate it. This study presents a retrospective analysis to evaluate the therapeutic efficacy and safety of adjusting the administration frequency of fruquintinib in patients with mCRC.

Methods

We conducted a retrospective analysis of the follow-up data and clinicopathological characteristics of 99 patients with mCRC who wer

SUBMITTER: Zhang Q 

PROVIDER: S-EPMC12078818 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature